Trial of Novel, On-Demand Virtual Reality to Amplify Practice Efficacy (NO VAPE) Added to Cognitive Behavioral Therapy for Nicotine Vaping Cessation

NCT07223879 | Not Yet Recruiting

• 2 other identifiers: Pro000872164R44DA059018-02
• Study Type: interventional
• Target: 90
• Locations: 0 countries
• Sites: N/A

Brief Summary

3\. General Description of Study Design The proposed study will evaluate the effect of adding a VR app with CBT-embedded content to a 12-session individual CBT treatment program. Investigators propose a prospective, randomized, single-blind, trial with 90 individuals aged 16 years and over who vape nicotine at least weekly for three months, and wish to quit vaping within the next month. Subjects will be randomly assigned to either the experimental (NO VAPE + CBT) or control group (sham NO VAPE + CBT) for 12 weeks. The study will use a double blind design where both subjects and investigators and outcome assessors will be masked to subjects' group assignments. The experimental group will receive the following over a 12-week period: NO VAPE (VR app) combined with the MGH 12-session remote behavioral vaping cessation support program for vaping cessation. The control group will receive a sham NO VAPE (VR app) combined with the MGH 12-session remote behavioral vaping cessation support program. The VR app will be used at home by participants in between CBT session visits. Participants will also briefly report their CBT skills practice using the MyCap smartphone app. Participants will be assigned randomly to the experimental or control group in a 1:1 ratio, with randomization blocks of 6, stratified by no/mild nicotine dependence (Electronic Cigarette Dependence Index \[ECDI\] score 0-8) or moderate/high nicotine dependence (ECDI score 9 or higher) in a prospective trial in people age 16 and over, who use vaped nicotine regularly and wish to quit vaping. The primary outcome is self-reported time spent in CBT skills practice per week. Groups will be compared on mean number of days and duration of self-reported CBT skill practice per week over the 12-week treatment period. Secondary outcomes are: tolerability and feasibility of the NO VAPE virtual reality (VR) vaping cessation tool, which will be assessed by the following self-reported ratings in both groups: a) average CBT session attendance weekly, b) satisfaction ratings, c) adverse events; and by the following self-reported ratings d) self-ratings of the virtual reality application usability, e) engagement, f) presence, and g) simulator cyber sickness. Exploratory outcomes are: 1) biochemically verified 7-day point prevalence vaping abstinence at week 12, and 2) 4-week biochemically verified continuous abstinence from weeks 9-12.

Conditions

NO VAPE + 12 Weeks of Standard CBT; Sham NO VAPE + 12 Weeks Standard CBT

Outcome Measures

Primary Outcomes (2)

• Difference in CBT sessions attended

  We will evaluate the number of CBT sessions attended across the 12 weeks

  12 Weeks

• Time spent practicing CBT skills

  We time spent practicing CBT between sessions in minutes. The app collects data automatically on how much time is spent using it, and how much time is spent within each environment.

  Weeks 1-12

Secondary Outcomes (3)

• Change in craving

  Weeks 1-12

• Change in withdrawal symptoms

  Weeks 1-12

• Change in severity of tobacco use disorder (TUD)

  Week 12

Other Outcomes (2)

• 7-Day Point Prevalence Vaping Abstinence

  week 12

• 4-Week Vaping Abstinence

  weeks 9-12

Study Arms (2)

NO VAPE + 12 weeks CBT

ACTIVE COMPARATOR

The experimental group will receive the following over a 12-week period: NO VAPE (VR app) combined with the MGH 12-session remote behavioral vaping cessation support program for vaping cessation.

Behavioral: NO VAPE VR app with CBT-embedded content with a 12-session individual CBT treatment program

Sham NO VAPE + 12 weeks CBT

SHAM COMPARATOR

The control group will receive a sham NO VAPE (VR app) combined with the MGH 12-session remote behavioral vaping cessation support program.

Behavioral: Sham VR app without CBT-embedded content with a 12-session individual CBT treatment program

Interventions

NO VAPE VR app with CBT-embedded content with a 12-session individual CBT treatment program BEHAVIORAL

The control group will receive a sham NO VAPE (VR app) combined with the MGH 12-session remote behavioral vaping cessation support program.

NO VAPE + 12 weeks CBT

Sham VR app without CBT-embedded content with a 12-session individual CBT treatment program BEHAVIORAL

The control group will receive a sham NO VAPE (VR app) combined with the MGH 12-session remote behavioral vaping cessation support program.

Sham NO VAPE + 12 weeks CBT

Eligibility Criteria

• Age: 16 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 16 years or older
• Report of nicotine vaping at least weekly for the prior ≥ 3 months
• Self-report of not smoking tobacco regularly at enrollment (tobacco smoking on \<8 of the past 30 days)
• Report motivation to quit vaping in the next 30 days
• Own or are willing to use a Meta Quest VR headset
• Vision corrected to within 20/50 bilaterally
• Access to a mobile device to complete daily survey assessments
• If age is greater than or equal to 18 years: Competent and willing to provide written informed consent
• If age is less than 18 years: Competent and willing to provide written informed assent AND have a parent/legal guardian who is competent and willing to provide written informed consent

You may not qualify if:

• Individuals at greater risk of harm from virtual reality side effects, such as a history of motion sickness, history of migraines or severe headaches, history of vertigo, epilepsy or neurological conditions where visual stimuli may trigger seizures or other issues (excludes history of febrile seizures), or self-report of pregnancy, recent concussion, or other conditions that increase risks of dizziness, nausea, or headaches
• Evidence of active problem substance use severe enough, in the investigator's opinion, to compromise ability to safely participate
• Unwilling to provide saliva or urine samples
• Any condition or situation that would, in the investigator's opinion, make it unlikely that the participant could adhere safely to the study protocol
• Individuals who are under the legal protection of the government or state (Wards of the State)
• Inability to understand study procedures, read, and write in English

Sponsors & Collaborators

• Charles River Analytics: lead
• National Institute on Drug Abuse (NIDA): collaborator
• Massachusetts General Hospital: collaborator

Related Publications (26)

• Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30.

  PMID: 18929686 BACKGROUND

• Kennedy RS, Lane NE, Berbaum KS, Lilienthal MG. Simulator Sickness Questionnaire: An Enhanced Method for Quantifying Simulator Sickness. The International Journal of Aviation Psychology. 1993/07/01 1993;3(3):203-220. doi:10.1207/s15327108ijap0303_3

  BACKGROUND

• Witmer BG, Singer MJ. Measuring Presence in Virtual Environments: A Presence Questionnaire. Presence: Teleoperators and Virtual Environments. 1998;7(3):225-240. doi:10.1162/105474698565686

  BACKGROUND

• Lin JJW, Duh HBL, Parker DE, Abi-Rached H, Furness TA. Effects of field of view on presence, enjoyment, memory, and simulator sickness in a virtual environment. 2002:164-171.

  BACKGROUND

• Schuster RM, Cather C, Pachas GN, Nielsen L, Iroegbulem V, Dufour J, Potter K, Levy S, Gray KM, Evins AE. A randomized controlled trial of varenicline and brief behavioral counseling delivered by lay counselors for adolescent vaping cessation: Study protocol. Front Psychiatry. 2023 Mar 15;14:1083791. doi: 10.3389/fpsyt.2023.1083791. eCollection 2023.

  PMID: 37009114 BACKGROUND

• Meta. This is Meta Quest. Accessed 03/05/2025, 2025. https://www.meta.com/quest/?srsltid=AfmBOoojbfuf4Ht9amTr-QDOGrgC5wz7RHJ80CTGLUZ4bQ0IKlyr_V8w

  BACKGROUND

• Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986 Mar;43(3):289-94. doi: 10.1001/archpsyc.1986.01800030107013.

  PMID: 3954551 BACKGROUND

• Dowd AN, Motschman CA, Tiffany ST. Development and Validation of the Questionnaire of Vaping Craving. Nicotine Tob Res. 2019 Jan 1;21(1):63-70. doi: 10.1093/ntr/nty046.

  PMID: 29546379 BACKGROUND

• Piper ME, Baker TB, Benowitz NL, Smith SS, Jorenby DE. E-cigarette Dependence Measures in Dual Users: Reliability and Relations With Dependence Criteria and E-cigarette Cessation. Nicotine Tob Res. 2020 Apr 21;22(5):756-763. doi: 10.1093/ntr/ntz040.

  PMID: 30874804 BACKGROUND

• Adamson SJ, Kay-Lambkin FJ, Baker AL, Lewin TJ, Thornton L, Kelly BJ, Sellman JD. An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Drug Alcohol Depend. 2010 Jul 1;110(1-2):137-43. doi: 10.1016/j.drugalcdep.2010.02.017. Epub 2010 Mar 26.

  PMID: 20347232 BACKGROUND

• Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993 Jun;88(6):791-804. doi: 10.1111/j.1360-0443.1993.tb02093.x.

  PMID: 8329970 BACKGROUND

• Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998 Sep 14;158(16):1789-95. doi: 10.1001/archinte.158.16.1789.

  PMID: 9738608 BACKGROUND

• Robinson SM, Sobell LC, Sobell MB, Leo GI. Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav. 2014 Mar;28(1):154-62. doi: 10.1037/a0030992. Epub 2012 Dec 31.

  PMID: 23276315 BACKGROUND

• Wienrich C, Döllinger N, Hein R. Behavioral Framework of Immersive Technologies (BehaveFIT): How and Why Virtual Reality can Support Behavioral Change Processes. Hypothesis and Theory. Frontiers in Virtual Reality. 2021-June-24 2021;2doi:10.3389/frvir.2021.627194

  BACKGROUND

• Okpako T, Kale D, Perski O, Brown J. Prevalence and characteristics of smokers interested in using virtual reality for encouraging smoking cessation: a representative population survey in Great Britain. BMC Digital Health. 2024/11/12 2024;2(1):79. doi:10.1186/s44247-024-00136-2

  BACKGROUND

• Pericot-Valverde I, Secades-Villa R, Gutierrez-Maldonado J, Garcia-Rodriguez O. Effects of systematic cue exposure through virtual reality on cigarette craving. Nicotine Tob Res. 2014 Nov;16(11):1470-7. doi: 10.1093/ntr/ntu104. Epub 2014 Jun 23.

  PMID: 24962558 BACKGROUND

• Pericot-Valverde I, Secades-Villa R, Gutierrez-Maldonado J. A randomized clinical trial of cue exposure treatment through virtual reality for smoking cessation. J Subst Abuse Treat. 2019 Jan;96:26-32. doi: 10.1016/j.jsat.2018.10.003. Epub 2018 Oct 16.

  PMID: 30466545 BACKGROUND

• Pericot-Valverde I, Garcia-Rodriguez O, Gutierrez-Maldonado J, Ferrer-Garcia M, Secades-Villa R. Evolution of smoking urge during exposure through virtual reality. Stud Health Technol Inform. 2011;167:74-9.

  PMID: 21685645 BACKGROUND

• Mayer M, Reyes-Guzman C, Grana R, Choi K, Freedman ND. Demographic Characteristics, Cigarette Smoking, and e-Cigarette Use Among US Adults. JAMA Netw Open. 2020 Oct 1;3(10):e2020694. doi: 10.1001/jamanetworkopen.2020.20694.

  PMID: 33048127 BACKGROUND

• Wang P, Ai X, Zhang X, Ma F, Zhuang Y, Wang S. Evaluating virtual reality technology in psychotherapy: impacts on anxiety, depression, and ADHD. Front Psychiatry. 2024 Dec 18;15:1480788. doi: 10.3389/fpsyt.2024.1480788. eCollection 2024.

  PMID: 39744548 BACKGROUND

• Lindner P. Better, Virtually: the Past, Present, and Future of Virtual Reality Cognitive Behavior Therapy. International Journal of Cognitive Therapy. 2021/03/01 2021;14(1):23-46. doi:10.1007/s41811-020-00090-7

  BACKGROUND

• Keijsers M, Vega-Corredor MC, Tomintz M, Hoermann S. Virtual Reality Technology Use in Cigarette Craving and Smoking Interventions (I "Virtually" Quit): Systematic Review. J Med Internet Res. 2021 Sep 17;23(9):e24307. doi: 10.2196/24307.

  PMID: 34533471 BACKGROUND

• Milkowski M, Olesk J, Asfura DM, et al. Youth Vaping in the Digital Age: A Systematic Review of Technological Interventions for Prevention and Cessation. presented at: Companion Proceedings of the 2025 ACM International Conference on Supporting Group Work; 2025; Hilton Head, New Jersey, USA. https://doi.org/10.1145/3688828.3699642

  BACKGROUND

• Obisesan OH, Osei AD, Uddin SMI, Dzaye O, Mirbolouk M, Stokes A, Blaha MJ. Trends in e-Cigarette Use in Adults in the United States, 2016-2018. JAMA Intern Med. 2020 Oct 1;180(10):1394-1398. doi: 10.1001/jamainternmed.2020.2817.

  PMID: 32897288 BACKGROUND

• Vahratian A, Briones EM, Jamal A, Marynak KL. Electronic Cigarette Use Among Adults in the United States, 2019-2023. NCHS Data Brief. 2025 Jan;(524):CS356607. doi: 10.15620/cdc/174583.

  PMID: 40036117 BACKGROUND

• Bandi P, Star J, Minihan AK, Patel M, Nargis N, Jemal A. Changes in E-Cigarette Use Among U.S. Adults, 2019-2021. Am J Prev Med. 2023 Aug;65(2):322-326. doi: 10.1016/j.amepre.2023.02.026. Epub 2023 Apr 18.

  PMID: 37479423 BACKGROUND

Central Study Contacts

Bethany Bracken

CONTACT

16174913474; bbracken@cra.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 24, 2025
• First Posted: November 3, 2025
• Study Start: November 1, 2025
• Primary Completion (Estimated): February 1, 2028
• Study Completion (Estimated): February 1, 2028
• Last Updated: November 3, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
• Time Frame: Feb 2029
• Access Criteria: They must request access through Charles River Analytics.